Cover Image
Market Research Report

Global Human Microbiome Therapeutics Market 2020-2024

Published by TechNavio (Infiniti Research Ltd.) Product code 938111
Published Content info 120 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Human Microbiome Therapeutics Market 2020-2024
Published: May 20, 2020 Content info: 120 Pages
Description

Technavio has been monitoring the human microbiome therapeutics market and it is poised to grow by USD 276.93 mn during 2020-2024 progressing at a CAGR of 15% during the forecast period. Our reports on human microbiome therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the growing prevalence of chronic diseases and robust pipeline. In addition, growing prevalence of chronic diseases is anticipated to boost the growth of the market as well.

The human microbiome therapeutics market analysis includes application segment and geographic landscapes

Technavio's ‘human microbiome therapeutics market ’ is segmented as below:

By Application:

  • Gastrointestinal disorders
  • Immunological conditions
  • Others

By Geographic Landscape:

  • North America
  • Europe
  • APAC
  • ROW

This study identifies the side effects of existing treatment as one of the prime reasons driving the human microbiome therapeutics market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our human microbiome therapeutics market covers the following areas:

  • Human microbiome therapeutics market sizing
  • Human microbiome therapeutics market forecast
  • Human microbiome therapeutics market industry analysis"

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading human microbiome therapeutics market vendors that include Bristol-Myers Squibb Co., Dow Inc., ENTEROME SA, Ferring Pharmaceuticals AS, Johnson & Johnson, Kaleido Biosciences Inc., PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc., and Takeda Pharmaceutical Co. Ltd.. Also, the human microbiome therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents
Product Code: IRTNTR43730

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Application

  • Market segments
  • Comparison by Application
  • Gastrointestinal disorders - Market size and forecast 2019-2024
  • Immunological conditions - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by application

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • APAC - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Bristol-Myers Squibb Co.
  • Dow Inc.
  • ENTEROME SA
  • Ferring Pharmaceuticals AS
  • Johnson & Johnson
  • Kaleido Biosciences Inc.
  • PureTech Health Plc
  • Second Genome Therapeutics
  • Seres Therapeutics Inc.
  • Takeda Pharmaceutical Co. Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ million)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Application - Market share 2019-2024 (%)
  • 22: Comparison by Application
  • 23: Gastrointestinal disorders - Market size and forecast 2019-2024 ($ million)
  • 24: Gastrointestinal disorders - Year-over-year growth 2019-2024 (%)
  • 25: Immunological conditions - Market size and forecast 2019-2024 ($ million)
  • 26: Immunological conditions - Year-over-year growth 2019-2024 (%)
  • 27: Others - Market size and forecast 2019-2024 ($ million)
  • 28: Others - Year-over-year growth 2019-2024 (%)
  • 29: Market opportunity by Application
  • 30: Customer landscape
  • 31: Market share by geography 2019-2024 (%)
  • 32: Geographic comparison
  • 33: North America - Market size and forecast 2019-2024 ($ million)
  • 34: North America - Year-over-year growth 2019-2024 (%)
  • 35: Europe - Market size and forecast 2019-2024 ($ million)
  • 36: Europe - Year-over-year growth 2019-2024 (%)
  • 37: APAC - Market size and forecast 2019-2024 ($ million)
  • 38: APAC - Year-over-year growth 2019-2024 (%)
  • 39: ROW - Market size and forecast 2019-2024 ($ million)
  • 40: ROW - Year-over-year growth 2019-2024 (%)
  • 41: Key leading countries
  • 42: Market opportunity by geography ($ million)
  • 43: Impact of drivers and challenges
  • 44: Vendor landscape
  • 45: Landscape disruption
  • 46: Industry risks
  • 47: Vendors covered
  • 48: Market positioning of vendors
  • 49: Bristol-Myers Squibb Co. - Overview
  • 50: Bristol-Myers Squibb Co. - Business segments
  • 51: Bristol-Myers Squibb Co. - Key offerings
  • 52: Bristol-Myers Squibb Co. - Key customers
  • 53: Bristol-Myers Squibb Co. - Segment focus
  • 54: Dow Inc. - Overview
  • 55: Dow Inc. - Business segments
  • 56: Dow Inc. - Key offerings
  • 57: Dow Inc. - Key customers
  • 58: Dow Inc. - Segment focus
  • 59: ENTEROME SA - Overview
  • 60: ENTEROME SA - Product and service
  • 61: ENTEROME SA - Key offerings
  • 62: ENTEROME SA - Key customers
  • 63: ENTEROME SA - Segment focus
  • 64: Ferring Pharmaceuticals AS - Overview
  • 65: Ferring Pharmaceuticals AS - Product and service
  • 66: Ferring Pharmaceuticals AS - Key offerings
  • 67: Ferring Pharmaceuticals AS - Key customers
  • 68: Ferring Pharmaceuticals AS - Segment focus
  • 69: Johnson & Johnson - Overview
  • 70: Johnson & Johnson - Business segments
  • 71: Johnson & Johnson - Key offerings
  • 72: Johnson & Johnson - Key customers
  • 73: Johnson & Johnson - Segment focus
  • 74: Kaleido Biosciences Inc. - Overview
  • 75: Kaleido Biosciences Inc. - Product and service
  • 76: Kaleido Biosciences Inc. - Key offerings
  • 77: Kaleido Biosciences Inc. - Key customers
  • 78: Kaleido Biosciences Inc. - Segment focus
  • 79: PureTech Health Plc - Overview
  • 80: PureTech Health Plc - Business segments
  • 81: PureTech Health Plc - Key offerings
  • 82: PureTech Health Plc - Key customers
  • 83: PureTech Health Plc - Segment focus
  • 84: Second Genome Therapeutics - Overview
  • 85: Second Genome Therapeutics - Product and service
  • 86: Second Genome Therapeutics - Key offerings
  • 87: Second Genome Therapeutics - Key customers
  • 88: Second Genome Therapeutics - Segment focus
  • 89: Seres Therapeutics Inc. - Overview
  • 90: Seres Therapeutics Inc. - Product and service
  • 91: Seres Therapeutics Inc. - Key offerings
  • 92: Seres Therapeutics Inc. - Key customers
  • 93: Seres Therapeutics Inc. - Segment focus
  • 94: Takeda Pharmaceutical Co. Ltd. - Overview
  • 95: Takeda Pharmaceutical Co. Ltd. - Product and service
  • 96: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 97: Takeda Pharmaceutical Co. Ltd. - Key customers
  • 98: Takeda Pharmaceutical Co. Ltd. - Segment focus
  • 99: Currency conversion rates for US$
  • 100: Research Methodology
  • 101: Validation techniques employed for market sizing
  • 102: Information sources
  • 103: List of abbreviations
Back to Top